NVNefeli Valyraki

Nefeli Valyraki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nefeli Valyraki has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • A. Schmitt

    Service d'Hematologie, Institut Bergonie, Bordeaux, France

    1 shared publication
  • Adrien ter Schiphorst

    Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Team Turc, Paris, France

    1 shared publication
  • Adrián Valls Carbó

    Department of Neurosciencies, Germans Trias I Pujol University Hospital, Badalona, Spain (A.V.C., M.H.-P.).

    1 shared publication
  • Alberto Picca

    Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau - Paris Brain Institute (ICM), AP-HP, Pitié Salpêtrière University Hospital, Paris, France

    1 shared publication
  • Anne Wacongne

    Neurology Department, CHU Nimes, France

    1 shared publication
  • B. Mathon

    Inserm, CNRS, UMR S 1127, service de neurochirurgie, institut du cerveau et de la moelle épinière, IHU, ICM, hôpital Pitié-Salpêtrière, AP-HP, Sorbonne université, Paris, France

    1 shared publication

Latest Publications

  • Open Access

    Core Blood-Brain Barrier Disruption in Patients With Large Vessel Occlusion

    by Richard Leigh, Nefeli Valyraki, Nae-Yuh Wang, Manar Abomulay, Adrien ter Schiphorst, Adrián Valls Carbó, María Hernández-Pérez, Frédérique Charbonneau, Caroline Arquizan, Anne Wacongne, et al.

    BACKGROUND: Multimodal imaging has expanded treatment for patients with acute ischemic stroke with large vessel occlusion. Blood-brain barrier (BBB) disruption measured in the ischemic core is associated with hemorrhagic transformation. However, the associations between core BBB disruption (cBBBD) and baseline clinical/imaging variables, as well as 3-month outcome, have not been explored. METHODS: This is a retrospective multicenter analysis of consecutive anterior circulation patients with acute ischemic stroke with large vessel occlusion, presenting over a 4-year time period, who were transferred from a primary to a comprehensive stroke center for possible endovascular therapy, with magnetic resonance imaging that included perfusion-weighted imaging before transfer. Magnetic resonance imaging scans were processed using RAPID software to generate penumbral imaging variables. Perfusion-weighted images were processed to detect and quantify contrast leakage; cBBBD was calculated as the average of all leaky voxels in the ischemic core. Poor functional outcome was defined as a modified Rankin Scale score of >2 at 3 months. Linear regression was used except for the outcome, which used logistic regression, controlling for age, stroke severity, and baseline functional status. RESULTS: Out of 411 patients transferred for endovascular therapy, 291 were included in this analysis with a median age of 74 years; 49% were female patients. The median National Institutes of Health Stroke Scale score was 13, the mean core volume was 32.3 mL, and the mean cBBBD was 2.1%. 71% of patients underwent endovascular therapy. Admission National Institutes of Health Stroke Scale score ( P P =0.033) were independently correlated with cBBBD. All imaging variables correlated strongly with cBBBD ( P r 2 =0.254). Increasing cBBBD was independently associated with poor functional outcome (adjusted odds ratio, 1.16 [CI, 1.03–1.32]; P =0.019; n=279), indicating that for every 1% increase in cBBBD, the odds of having a poor functional outcome increase by 16%. CONCLUSIONS: In acute ischemic stroke with large vessel occlusion, disruption of the BBB in the core lesion is independently associated with clinical outcome. cBBBD represents a new imaging profile for acute stroke that may help guide treatments.


  • Primary central nervous system lymphoma of the spinal cord: A LOC network cohort study

    by N. Valyraki, G. Ahle, E. Tabouret, R. Houot, F. Jardin, H. Ghesquières, A. Schmitt, J. Paillassa, S. Choquet, C. Soussain, et al.


  • Open Access

    Anti–Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors

    by Alberto Picca, Nefeli Valyraki, Cristina Birzu, Nora Kramkimel, Olivier Hermine, Noel Zahr, Giulia Berzero, Dimitri Psimaras

    Background and Objectives To describe the marked clinical and biological responses of a targeted treatment with anti–interleukin-6 (IL-6)–receptor antibody and Janus kinase (JAK) inhibitors in a patient with a severe, corticoresistant CNS toxicity of immune-checkpoint inhibitor (ICI) therapy. Methods A 58-year-old man was admitted for subacute paraparesis, urinary retention, and ascending paresthesia. He was under treatment with ipilimumab and nivolumab for metastatic melanoma. Spine MRI disclosed multiple T2-hyperintense, contrast-enhancing longitudinally extensive lesions. A diagnosis of ICI-related acute transverse myelitis was made. Results ICIs were immediately discontinued, and the patient received high-dose glucocorticoids plus 1 session of plasma exchange, but he did not improve. Based on the marked elevation of CSF IL-6 (505 pg/mL), a second-line targeted therapy with anti-IL-6-receptor tocilizumab (8 mg/kg/mo for 3 infusions) plus JAK inhibitor ruxolitinib (50 mg/d) was administered. Patient neurologic status started to improve shortly after, with corresponding radiologic resolution. At 9 months, the patient was able to walk independently, presenting only slight residual disability while remaining in oncologic partial response. Discussion Our case suggests that some patients with severe, corticoresistant CNS immune-related toxicities of ICIs may benefit from cytokine blockade. Cytokine measurement in serum and CSF might help in selecting patients for personalized treatment strategies.